PL2483416T3 - Przeciwciała monoklonalne - Google Patents

Przeciwciała monoklonalne

Info

Publication number: PL2483416T3
Authority: PL; Poland
Prior art keywords: monoclonal antibodies; monoclonal; antibodies
Prior art date: 2009-10-02

Application number

PL10821238T

Other languages

English (en)

Inventor

Katerina Akassoglou

Original Assignee

The Regents Of The University Of California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-02

Filing date

2010-09-30

Publication date

2017-05-31

2010-09-30 Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California

2017-05-31 Publication of PL2483416T3 publication Critical patent/PL2483416T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Genetics & Genomics (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL10821238T 2009-10-02 2010-09-30 Przeciwciała monoklonalne PL2483416T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US24801409P	2009-10-02	2009-10-02

Publications (1)

Publication Number	Publication Date
PL2483416T3 true PL2483416T3 (pl)	2017-05-31

Family

ID=43826649

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10821238T PL2483416T3 (pl)	2009-10-02	2010-09-30	Przeciwciała monoklonalne

Country Status (38)

Country	Link
US (1)	US8877195B2 (pl)
EP (1)	EP2483416B1 (pl)
JP (1)	JP5883389B2 (pl)
KR (1)	KR101793221B1 (pl)
CN (1)	CN102575277B (pl)
AR (1)	AR078490A1 (pl)
AU (1)	AU2010300559B2 (pl)
BR (1)	BR112012008370B8 (pl)
CA (1)	CA2774256C (pl)
CL (1)	CL2012000788A1 (pl)
CO (1)	CO6440561A2 (pl)
CR (1)	CR20120127A (pl)
CY (1)	CY1118540T1 (pl)
DK (1)	DK2483416T3 (pl)
DO (1)	DOP2012000089A (pl)
EA (1)	EA023477B1 (pl)
ES (1)	ES2614939T3 (pl)
GE (2)	GEP20166458B (pl)
GT (1)	GT201200096A (pl)
HK (1)	HK1168871A1 (pl)
HR (1)	HRP20170110T1 (pl)
HU (1)	HUE031571T2 (pl)
IL (1)	IL218621B (pl)
IN (1)	IN2012DN03154A (pl)
LT (1)	LT2483416T (pl)
MA (1)	MA33704B1 (pl)
MX (1)	MX2012003811A (pl)
MY (1)	MY159359A (pl)
NZ (1)	NZ598770A (pl)
PL (1)	PL2483416T3 (pl)
PT (1)	PT2483416T (pl)
SI (1)	SI2483416T1 (pl)
SM (1)	SMT201700083B (pl)
TN (1)	TN2012000149A1 (pl)
TW (1)	TWI511741B (pl)
UA (1)	UA108860C2 (pl)
WO (1)	WO2011041518A1 (pl)
ZA (1)	ZA201202227B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8771693B2 (en)	2009-10-27	2014-07-08	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for the generation and use of conformation-specific antibodies
CN103702967A (zh)	2011-03-14	2014-04-02	貝丝以色列女执事医疗中心	用于治疗增殖性病症的方法和组合物
US10487114B2 (en)	2011-04-27	2019-11-26	Beth Israel Deaconess Medical Center, Inc.	Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
WO2012162698A1 (en)	2011-05-26	2012-11-29	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for the treatment of immune disorders
WO2013185055A1 (en)	2012-06-07	2013-12-12	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for the inhibition of pin1
ES2835716T3 (es)	2013-03-15	2021-06-23	Beth Israel Deaconess Medical Ct Inc	Procedimientos y composiciones para la generación y el uso de anticuerpos específicos de conformación
EP3091996B1 (en) *	2014-01-11	2024-04-10	The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone	Compositions and methods for in vitro assays of fibrin activity
WO2016011265A2 (en)	2014-07-17	2016-01-21	Beth Israel Deaconess Medical Center, Inc.	Biomarkers for pin1-associated disorders
WO2016011268A1 (en)	2014-07-17	2016-01-21	Beth Israel Deaconess Medical Center, Inc.	Atra for modulating pin1 activity and stability
US10548864B2 (en)	2015-03-12	2020-02-04	Beth Israel Deaconess Medical Center, Inc.	Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
EP3620471A4 (en) *	2017-05-02	2021-01-06	National Cancer Center Japan	ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE
JPWO2021200932A1 (pl) *	2020-03-31	2021-10-07
WO2022133028A1 (en) *	2020-12-16	2022-06-23	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Use of fibrin-targeting immunotherapy to reduce coronavirus pathogenesis
WO2022159776A1 (en) *	2021-01-21	2022-07-28	Therini Bio, Inc.	Antibodies which bind human fibrin and methods of use
WO2022266539A2 (en) *	2021-06-18	2022-12-22	Therini Bio, Inc.	ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
US20240279321A1 (en) *	2021-06-18	2024-08-22	Therini Bio, Inc.	ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE
WO2024044583A1 (en) *	2022-08-22	2024-02-29	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Human anti-fibrin antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030031675A1 (en) *	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
PL2314621T3 (pl) *	2004-05-27	2014-08-29	Crucell Holland Bv	Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
US7807645B2 (en) *	2005-09-23	2010-10-05	The Regents Of The University Of California	Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment

2010
- 2010-09-30 EA EA201270416A patent/EA023477B1/ru unknown
- 2010-09-30 GE GEAP201013232A patent/GEP20166458B/en unknown
- 2010-09-30 JP JP2012532307A patent/JP5883389B2/ja active Active
- 2010-09-30 BR BR112012008370A patent/BR112012008370B8/pt active IP Right Grant
- 2010-09-30 GE GEAP201012676A patent/GEP20156214B/en unknown
- 2010-09-30 KR KR1020127011293A patent/KR101793221B1/ko active IP Right Grant
- 2010-09-30 AU AU2010300559A patent/AU2010300559B2/en active Active
- 2010-09-30 DK DK10821238.2T patent/DK2483416T3/en active
- 2010-09-30 WO PCT/US2010/050873 patent/WO2011041518A1/en active Application Filing
- 2010-09-30 MX MX2012003811A patent/MX2012003811A/es active IP Right Grant
- 2010-09-30 CN CN201080046037.8A patent/CN102575277B/zh active Active
- 2010-09-30 HU HUE10821238A patent/HUE031571T2/en unknown
- 2010-09-30 ES ES10821238.2T patent/ES2614939T3/es active Active
- 2010-09-30 PL PL10821238T patent/PL2483416T3/pl unknown
- 2010-09-30 MY MYPI2012001408A patent/MY159359A/en unknown
- 2010-09-30 EP EP10821238.2A patent/EP2483416B1/en active Active
- 2010-09-30 LT LTEP10821238.2T patent/LT2483416T/lt unknown
- 2010-09-30 UA UAA201203044A patent/UA108860C2/ru unknown
- 2010-09-30 CA CA2774256A patent/CA2774256C/en active Active
- 2010-09-30 NZ NZ598770A patent/NZ598770A/en unknown
- 2010-09-30 SI SI201031390A patent/SI2483416T1/sl unknown
- 2010-09-30 PT PT108212382T patent/PT2483416T/pt unknown
- 2010-10-01 TW TW099133559A patent/TWI511741B/zh active
- 2010-10-01 AR ARP100103578A patent/AR078490A1/es not_active Application Discontinuation
2012
- 2012-03-14 IL IL218621A patent/IL218621B/en not_active IP Right Cessation
- 2012-03-16 CR CR20120127A patent/CR20120127A/es unknown
- 2012-03-20 US US13/425,020 patent/US8877195B2/en active Active
- 2012-03-27 ZA ZA2012/02227A patent/ZA201202227B/en unknown
- 2012-03-29 DO DO2012000089A patent/DOP2012000089A/es unknown
- 2012-03-30 TN TNP2012000149A patent/TN2012000149A1/en unknown
- 2012-03-30 CL CL2012000788A patent/CL2012000788A1/es unknown
- 2012-03-30 GT GT201200096A patent/GT201200096A/es unknown
- 2012-04-12 IN IN3154DEN2012 patent/IN2012DN03154A/en unknown
- 2012-04-18 CO CO12064155A patent/CO6440561A2/es active IP Right Grant
- 2012-04-30 MA MA34824A patent/MA33704B1/fr unknown
- 2012-09-27 HK HK12109512.6A patent/HK1168871A1/zh unknown
2017
- 2017-01-23 HR HRP20170110TT patent/HRP20170110T1/hr unknown
- 2017-01-30 CY CY20171100132T patent/CY1118540T1/el unknown
- 2017-02-08 SM SM201700083T patent/SMT201700083B/it unknown

Also Published As

Publication number	Publication date
AU2010300559B2 (en)	2014-11-27
JP2013506425A (ja)	2013-02-28
TN2012000149A1 (en)	2013-09-19
KR20120094924A (ko)	2012-08-27
BR112012008370B1 (pt)	2020-12-22
MY159359A (en)	2016-12-30
IN2012DN03154A (pl)	2015-09-18
SI2483416T1 (sl)	2017-06-30
ES2614939T3 (es)	2017-06-02
GT201200096A (es)	2014-12-23
NZ598770A (en)	2014-01-31
LT2483416T (lt)	2017-04-25
IL218621B (en)	2018-07-31
CR20120127A (es)	2012-05-28
EP2483416B1 (en)	2016-11-23
BR112012008370B8 (pt)	2021-05-25
SMT201700083B (it)	2017-03-08
CA2774256C (en)	2019-02-19
TW201116298A (en)	2011-05-16
HRP20170110T1 (hr)	2017-03-24
DOP2012000089A (es)	2012-06-30
CO6440561A2 (es)	2012-05-15
US8877195B2 (en)	2014-11-04
WO2011041518A1 (en)	2011-04-07
PT2483416T (pt)	2017-02-14
US20120183560A1 (en)	2012-07-19
AU2010300559A1 (en)	2012-04-05
KR101793221B1 (ko)	2017-11-02
EA023477B1 (ru)	2016-06-30
HK1168871A1 (zh)	2013-01-11
UA108860C2 (xx)	2015-06-25
CA2774256A1 (en)	2011-04-07
MA33704B1 (fr)	2012-10-01
JP5883389B2 (ja)	2016-03-15
HUE031571T2 (en)	2017-07-28
CN102575277A (zh)	2012-07-11
AR078490A1 (es)	2011-11-09
GEP20166458B (en)	2016-04-11
CL2012000788A1 (es)	2012-09-14
DK2483416T3 (en)	2017-02-20
TWI511741B (zh)	2015-12-11
CY1118540T1 (el)	2017-07-12
BR112012008370A2 (pt)	2016-11-29
IL218621A0 (en)	2012-05-31
CN102575277B (zh)	2015-07-29
EA201270416A1 (ru)	2012-08-30
MX2012003811A (es)	2012-05-08
GEP20156214B (en)	2015-01-12
ZA201202227B (en)	2014-11-26
EP2483416A4 (en)	2013-06-26
EP2483416A1 (en)	2012-08-08

Publication	Publication Date	Title
EP2331579A4 (en)	2013-01-23	MONOCLONAL ANTIBODIES
IL214996A0 (en)	2011-11-30	Anti-bcma antibodies
GB0920127D0 (en)	2009-12-30	Antibodies
HK1168871A1 (zh)	2013-01-11	單克隆抗體
GB0909906D0 (en)	2009-07-22	Antibodies
IL207217A0 (en)	2010-12-30	Humanized anti-c5ar antibodies
SG10201601279SA (en)	2016-03-30	Monoclonal Antibody STRO-4
ZA201104545B (en)	2012-03-28	Anti-siglec-15 antibody
IL217919A0 (en)	2012-03-29	Humanized anti-cdcp1 antibodies
IL218724A0 (en)	2012-06-28	Endoglin antibodies
IL216147A0 (en)	2012-01-31	Humanized axl antibodies
EP2427496A4 (en)	2013-05-15	ANTI-VEGF-D ANTIBODIES
EP2412808A4 (en)	2013-01-23	BISPECIFIC ANTIBODY TYPE LH
EP2424891A4 (en)	2013-03-06	MONOCLONAL ERG ANTIBODIES
GB0920324D0 (en)	2010-01-06	Antibodies
HK1170745A1 (en)	2013-03-08	Antibodies against il-17br il-17br
EP2495319A4 (en)	2013-07-03	MONOCLONAL ANTIBODY SPECIFIC TO INTEGRIN alpha8beta1
GB2473934B (en)	2012-11-28	Anti-VEEV antibody
IL214755A0 (en)	2011-11-30	Anti-rhesus d monoclonal antibody
EP2499256A4 (en)	2013-09-11	ANTI-C-MPL ANTIBODIES
EP2424892A4 (en)	2012-12-19	DC-STAMP ANTIBODY
GB0908945D0 (en)	2009-07-01	Antibodies
GB0911712D0 (en)	2009-08-19	Antibody
GB0804684D0 (en)	2008-04-16	Humanized antibody
GB0804686D0 (en)	2008-04-16	Humanized antibody